The Alphavaxers: Dynavax And Novavax -- Facing The Shadow
@HaroldAnderson：
With the pandemic bottom of mind, it's time to check in on the Alphavaxers. Dynavax (NASDAQ:$(DVAX)$) and Novavax (NASDAQ:NVAX) were two pandemic darlings. In this article I report how they are faring inthis new normal as reflected by their Q3, 2022 earnings reports. Both are reliant on future pandemic related revenues, with Dynavax insulated to some extent by its HEPLISAV-B.Dynavax and Novavax Q3 earnings are all about performance.DynavaxAs I have come to expect Dynavax Q3 earnings as reported in its 11/03/2022 Q3, 2022 earnings call ("Call D") and presentation ("Presentation D")exceededmarket expectations. Its earnings reflected a $0.10 beat of expectations with its revenues beating by $8.33 million.Dynavax revenues are made up of two components:HEPLISAV-B vaccine net product revenue of
